Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT02030444 Terminated - Lung Neoplasms Clinical Trials

Extensive Staging in Lung Cancer

ExtStaging
Start date: August 2014
Phase: N/A
Study type: Interventional

The overall aim of this study is to compare standard staging of lung cancer (which includes clinical examination, CT, MRI, bone scan and PET-CT) with comprehensive staging - which includes the new staging methods (PET-MRI and systematic mapping of mediastinal and hilar lymph nodes using endobronchial ultrasound) with respect to disease stage and outcomes of therapy.

NCT ID: NCT02029690 Terminated - Clinical trials for Hepatocellular Carcinoma

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

TRAP
Start date: April 23, 2014
Phase: Phase 1
Study type: Interventional

A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort only), non-squamous non-small cell lung carcinoma stage IIIB/IV (NSCLC), metastatic uveal melanoma, hepatocellular carcinoma (HCC), glioma and sarcomatoid cancers

NCT ID: NCT02025218 Terminated - Lung Cancer Clinical Trials

Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients

IRENE
Start date: January 2014
Phase: Phase 2
Study type: Interventional

To evaluate the effect of re-administration of gefitinib to EGFR-mutated NSCLC patients who had been treated with at least one line of TKIs followed by another line of treatment (non-TKI)

NCT ID: NCT02019979 Terminated - Clinical trials for Non-small Cell Lung Cancer Metastatic

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)

METRO
Start date: December 2013
Phase: Phase 2
Study type: Interventional

Metformin is thought to activate AMP-activated protein kinase (AMPK), a major sensor of cellular energy levels and a key enzyme limiting cellular growth during times of cellular stress. Once activated, this enzyme restricts anabolic processes such as protein, cholesterol and fatty acid synthesis and inhibits mTOR, a protein kinase responsible for unregulated growth. MTOR is upregulated in a variety of tumors, including NSCLC providing rationale to take advantage of this pathway with metformin.

NCT ID: NCT02011087 Terminated - Clinical trials for Extensive Stage Small Cell Lung Cancer

Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

Start date: February 2014
Phase: N/A
Study type: Interventional

This clinical trial studies bioelectrical impedance phase angle in predicting treatment outcome in patients with extensive stage small cell lung cancer receiving first-line chemotherapy. Diagnostic procedures, such as bioelectrical impedance analysis, may help predict a patient's response to treatment for small cell lung cancer.

NCT ID: NCT01997775 Terminated - Clinical trials for Non-small Cell Lung Cancer

Metformin in Stage IV Lung Adenocarcinoma

Start date: August 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether metformin is effective in lowering plasma IL-6 level and improving the treatment response in patients with non-small cell lung cancer

NCT ID: NCT01992068 Terminated - Lung Cancer Clinical Trials

Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal Function

Start date: September 2013
Phase: N/A
Study type: Observational

The purpose of this study is to prospectively assess the feasibility of high-resolution manometry to identify radiation-induced changes in esophageal motility and contractility or "function" in patients undergoing radiation therapy for the treatment of locally advanced lung cancer.

NCT ID: NCT01952860 Terminated - Lung Cancer Clinical Trials

Hatha Yoga in Lung Cancer Couples

Start date: September 23, 2013
Phase: N/A
Study type: Interventional

The goal of this research study is to learn the opinion of patients and their caregiving about a couple-based Hatha Yoga program during treatment for cancer. Researchers also want to learn the effect of this program on lung function, distress, and quality of life.

NCT ID: NCT01939210 Terminated - Depression Clinical Trials

Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy

Start date: February 2010
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies the effects of meditation-based breathing training on patients' control of their breathing patterns and breathing-related movement, as well as on their psychological distress and treatment experience during radiation therapy. Meditation-based breathing training may decrease breathing-related movement and the amount of stress by improving breathing patterns in patients with abdominal or lung cancer undergoing radiation therapy.

NCT ID: NCT01935947 Terminated - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well azacitidine and entinostat before chemotherapy works in treating patients with non-small cell lung cancer that has spread to other places in the body. Drugs used in chemotherapy, such as azacitidine, irinotecan hydrochloride, gemcitabine hydrochloride, docetaxel, and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine and entinostat before chemotherapy may work better in treating patients with non-small cell lung cancer.